atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
Posted:
atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced a strategic investment in Beckley Psytech Limited (“Beckley Psytech”), a private clinical-stage biotechnology company dedicated to transforming short-duration psychedelics into effective and rapid-acting medicines for neuropsychiatric conditions.
At-home abortions should be allowed for up to 12 weeks of pregnancy across the UK, according to academics, after a study found they were just as safe and effective as hospital care.
Read more here.
To explore possible treatments for various diseases, either animal models or human cell cultures are usually used first; however, animal models do not always mimic human diseases well, and cultures are far removed from tissue complexity. Advances in 3D printing,…
Attendees
Sponsors and Exhibitors
Agenda 2025
Contact us